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Summary: Morphine is an analgesic drug used for the treatment of acute and chronic pain syndromes
for cancer patients. Glucuronidation is a major pathway of the elimination of morphine in humans.
Morphine is metabolized to 3-glucuronide (no analgesic eŠect) and 6-glucuronide (more potently
analgesic than morphine) mainly by UGT2B7. In the present study, we investigated the inhibitory eŠects
of a variety of drugs on the morphine glucuronosyltransferase activities in human liver microsomes.
Twenty-one drugs including anticancer drugs, immunosuppresants, analgesics, anticonvulsants,
antidepressants, antipsychotic drugs were selected in this study, because they are frequently co-
administered with morphine. We found that 10 out of 21 drugs, tamoxifen, tacrolimus, diclofenac,
carbamazepine, imipramine, clomipramine, amitriptyline, diazepam, lorazepam and oxazepam
extensively inhibited the morphine 3- and 6-glucuronosyltransferase activities. Although some of the
drugs are not substrates of UGT2B7, they would be potent inhibitors of UGT2B7. If patients receive
morphine and these drugs simultaneously, the drug-drug interaction may change the levels of morphine
and these glucuronides, resulting in altered analgesic e‹cacy and the risk of side eŠects. The results
presented here will assist clinicians in choosing the proper drugs andWor dosages, and enable them to
anticipate potential drug-drug interactions.
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Introduction
Morphine is an analgesic drug used for the treatment
of acute and chronic pain syndromes. It is used as the
most practical and versatile analgesic for the relief of
severe pain associated with advanced cancer in palliative
care.1) Morphine is extensively glucuronidated, and
this pathway accounts for approximately two-thirds of
the elimination of morphine in humans. Morphine
is metabolized to morphine 3- and 6-glucuronides by
UDP-glucuronosyltransferases (UGTs) in liver.2,3)
Morphine 3-glucuronidation is the dominant pathway.
The metabolic clearance to morphine 3-glucuronide is
about 5-fold higher than the metabolic clearance to
morphine 6-glucuronide.4) Morphine 3-glucuronide has
no analgesic eŠects, but morphine 6-glucuronide is a
more potent (20 times) analgesic than morphine itself.5)
Patients suŠering from cancer need continuous
therapy with morphine. Anti-cancer drugs such as
etoposide, irinotecan (its active metabolite is SN-38),
and tamoxifen, are widely used for chemotherapy with
morphine. Immunosuppressant drugs such as tacroli-
mus, cyclosporine A, and mycophenolate are sometimes
used with morphine for the treatment of pain after
organ transplantation. Cancer patients may also receive
analgesics (diclofenac, acetaminophen, and naloxone),
anticonvulsants (carbamazepine and valproic acid), and
antidepressants (imipramine, clomipramine, amitripty-
line, and desipramine) for the treatment of neuropathic
pain from cancer. In addition, 10–30z of cancer
patients have psychological distress.6,7) For the treat-
ment of the psychological distress, benzodiazepine
agonists (diazepam, lorazepam and oxazepam) and
antipsychorotic drugs (olanzapine and milnacipran) are
104 Yusuke HARA, et al.
used. Thus, morphine is frequently co-administered
with a variety of drugs. Since the clearance of morphine
is dependent on the metabolism by UGTs, drugs that
inhibit UGTs might aŠect the kinetics of morphine and
its glucuronides, resulting in altered analgesic e‹cacy
and the risk of side eŠects. In the present study, we
investigated the inhibitory eŠects of a variety of drugs
that are frequently co-administered with morphine, on
morphine glucuronidation in human livers in order to
obtain useful information for predicting drug-drug
interactions.
Materials and Methods
Chemicals and reagents: Morphine hydrochloride
was purchased from Takeda Chemical Industries
(Osaka, Japan). Morphine 3- and 6-glucuronides were
generous gifts from Dr. Kazuta Oguri, Kyushu Univer-
sity (Fukuoka, Japan). Etoposide, tamoxifen citrate,
cyclosporine A, mycophenolate, acetaminophen, val-
proic acid, carbamazepine, imipramine hydrochloride,
clomipramine hydrochloride, amitriptyline hydrochlo-
ride, desipramine hydrochloride, diazepam, lorazepam,
oxazepam were purchased from Wako Pure Chemical
Industries (Osaka, Japan). Diclofenac, naloxone,
uridine 5?-diphosphoglucronic acid (UDPGA), and
alamethicin were purchased from Sigma-Aldrich (St.
Louis, MO). Tacrolimus was purchased from Cal-
biochem (La Jolla, CA). Olanzapine was from Toronto
Research Chemicals (Toronto, Canada). Irinotecan and
SN-38 were kindly provided by Yakult (Tokyo, Japan).
Milnacipran hydrochloride was kindly provided by
Asahikasei Pharma (Tokyo, Japan). Pooled human
liver microsomes were obtained from BD Gentest
(Woburn, MA). All other chemicals were of the highest
grade commercially available.
Morphine glucuronosyltransferase activity: Mor-
phine glucuronosyltransferase activity was determined
as described previously8) with slight modiˆcations. A
typical incubation mixture (0.2 mL total volume)
contained 50 mM Tris-HCl buŠer (pH 7.4), 5 mM
MgCl2, 5 mM UDPGA, 25 mgWmL alamethicin, 0.25
mgWmL microsomal protein and 25–200 mM morphine.
Each drug, which was dissolved in methanol, was added
as an inhibitor so that the ˆnal concentration of solvent
in the incubation mixture was º1z. The reaction was
initiated by the addition of UDPGA. After incubation
at 379C for 30 min, the reaction was terminated by the
addition of 0.1 mL of ice-cold perchloric acid. After the
removal of protein by centrifugation at 10,000 g for 5
min, a 100 mL portion of the supernatant was subjected
to HPLC. Chromatography was performed using an
L-2130 pump (Hitachi, Tokyo, Japan), an L-2480 FL
detector (Hitachi), an L-2200 autosampler (Hitachi), a
D-2500 integrator (Hitachi), and an L-2300 column
oven (Hitachi). The ‰ow rate was 0.8 mLWmin and the
column temperature was 359C. The glucuronides were
detected ‰uorometrically (excitation: 210 nm; emission:
350 nm) with a noise-base clean Uni-3 (Union, Gunma,
Japan). The analytical column was a Develosil C30 (4.6
×150 mm; 5 mm) column (Nomura Chemical, Aichi,
Japan) and the mobile phase was 50 mM sodium
dihydrogen phosphate (pH 4.5). The retention times of
morphine 3-glucuronide, morphine 6-glucuronide, and
morphine were 18.5, 31.0 and 37.5 min, respectively.
The quantiˆcation of the metabolites was performed by
comparing the HPLC peak heights to those of authentic
standards. Limits of detection of morphine 3- and
6-glucuronides were 20 fmol and 200 fmol, respectively.
It was also conˆrmed that intra-day and inter-day
precision and accuracy of the detection of the
glucuronides were º10z (data not shown). The
formation of morphine 3- and 6-glucuronides by human
liver microsomes increased linearly with an incubation
time up to 60 min and with a protein concentration up
to 0.75 mgWmL. Unless speciˆed, an incubation time of
30 min and 0.25 mgWmL microsomal protein were used.
All data were analyzed using the mean of duplicate
determinations. The variances between the duplicate
determinations were º10z.
Data analyses: Lineweaver-Burk plots were used for
the determination of the type of inhibition,9) and Dixon
plots were used as a secondary method. Kinetic
parameters were determined by a nonlinear regression
analysis using a computer program (K-cat, BioMetal-
lics, Princeton, NJ).
Prediction of in vivo drug-drug interactions from in
vitro data: If an enzyme reaction is inhibited competi-
tively or noncompetitively by other drugs, when the
substrate concentration is much lower than Km, the
change in the intrinsic clearance (CLint) is expressed by
the following equation10):
CLint(＋inhibitor)WCLint(－inhibitor)＝1W(1＋IWKi )
where I is the concentration of the inhibitor and Ki is the
inhibition constant. When we discuss drug-drug interac-
tions via the inhibition of enzymes, it is important that
the concentration of the inhibitor refers to the
concentration of the drug around the enzyme. It is
di‹cult to know the actual concentrations of drugs at
the active site of UGT. The changes of CLint caused by
co-administered drugs can be predicted using the
maximum unbound concentrations in the liver. Since
data of the concentrations in the liver and protein
binding of each drug in tissues are largely not available,
the maximum plasma concentrations were alternatively
used in the present study.
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Fig. 1. Structure of drugs used in the present study.
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Fig. 1. Continued
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Results
Inhibitory eŠects of drugs on morphine glucuronosyl-
transferase activities in human liver microsomes:
Twenty-one drugs (500 mM) were screened for the
inhibitory eŠects on morphine 3- and 6-glucuronosyl-
transferase activities at a 50 mM substrate concentra-
tion. As shown in Fig. 2, the morphine 3- and 6-glu-
curonosyltransferase activities were strongly inhibited
by tamoxifen, diclofenac, imipramine, clomipramine,
amitriptyline, desipramine, diazepam, lorazepam and
oxazepam (º20z of control). The activities were also
moderately inhibited by tacrolimus, mycophenolate,
naloxone, carbamazepine, and olanzapine (20–50z
of control), and weakly inhibited by irinotecan
and valproic acid (50–70z of control). Interestingly,
the morphine glucuronosyltransferase activities were
activated by cyclosporine A (120z). For 14 drugs
showing À50z inhibition at 500 mM, the IC50 values
were determined by dose response curves with various
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Fig. 2. Inhibitory eŠects of drugs on morphine glucuronosyltransferase activities in human liver microsomes. The concentrations of morphine
and each drug were 50 mM and 500 mM, respectively. Each column represents the mean of duplicate determinations. The control activities in the
pooled human liver microsomes were 23.1 pmolWminWmg protein for morphine 3-glucuronosyltransferase activity and 5.4 pmolWminWmg protein
for morphine 6-glucuronosyltransferase activity. ND, not detected.
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concentrations. The IC50 values are summarized in
Fig. 2. The IC50 values of each drug were similar
between the morphine 3- and 6-glucuronosyltransferase
activities.
Inhibition constant and inhibition pattern: We
determined the inhibition constant (Ki ) values for 14
drugs that inhibited the morphine glucuronosyltrans-
ferase activities (IC50 values were º500 mM), (Fig. 3
and Table 1). The Kis and Kii values are inhibition
constants on the slope (competitive) and on the intercept
(noncompetitive), respectively. Tamoxifen, mycophe-
nolate, diclofenac, diazepam, and olanzapine exhibited
noncompetitive inhibition for both the morphine 3- and
6-glucuronosyltransferase activities. Tacrolimus, car-
bamazepine, and lorazepam exhibited a mixed type of
competitive and noncompetitive inhibition for both
activities. Naloxone, imipramine, clomipramine,
amitriptyline, and desipramine exhibited noncompeti-
tive and mixed type inhibitions for morphine 3- and 6-
glucuronosyltransferase activities, respectively. Oxazep-
am exhibited competitive and mixed type inhibitions for
morphine 3- and 6-glucuronosyltransferase activities,
respectively. All compounds except naloxone and
olanzapine more potently inhibited the morphine
6-glucuronosyltransferase activity than the morphine
3-glucuronosyltransferase activity.
Predicted change of in vivo clearance of morphine by
a variety of drugs from vitro data: To predict the
possibility of drug-drug interaction via a metabolic
process between morphine and the 14 drugs, the 1＋IWKi
values were calculated (Table 1). Carbamazepine
showed the highest 1＋IWKi values (1.4 and 1.9 for
morphine 3- and 6-glucuronosyltransferase activities,
respectively). The values by diclofenac were both 1.4
for morphine 3- and 6-glucuronosyltransferase activi-
ties. Mycophenolate, clomipramine, diazepam and
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Fig. 3. Typical Lineweaver-Burk plots of morphine glucuronosyltransferase activities in human liver microsomes. EŠects of oxazepam (A, B) or
naloxone (C, D) on morphine 3-(A, C) and 6-(B, D) glucuronosyltransferase activities were investigated. Each data point represents the mean of
duplicate determinations. Lines were drawn by linear regression analysis.
Table 1. Inhibition of morphine 3- and 6-glucuronosyltransferase activity in human liver microsomes by 14 drugs.
Morphine 3-glucuronosyltransferase activity Morphine 6-glucuronosyltransferase activity
Drug I ( mM)
Kis ( mM) Ki i ( mM) Inhibitory type 1＋IWKi Kis ( mM) Ki i ( mM) Inhibitory type 1＋IWKi
Tamoxifen 0.48 81 Noncompetitive 1.0 27 Noncompetitive 1.0
Tacrolimus 0.04 347 95 Mixed 1.0 101 46 Mixed 1.0
Mycophenolate 60 713 Noncompetitive 1.1 296 Noncompetitive 1.2
Diclofenac 9.4 22 Noncompetitive 1.4 24 Noncompetitive 1.4
Naloxone 0.05 518 Noncompetitive 1.0 1298 Competitive 1.0
Carbamazepine 42 243 118 Mixed 1.4 78 47 Mixed 1.9
Imipramine 1.9 81 Noncompetitive 1.0 60 33 Mixed 1.1
Clomipramine 1.4 20 Noncompetitive 1.1 19 6 Mixed 1.2
Amitriptyline 0.8 248 Noncompetitive 1.0 111 30 Mixed 1.0
Desipramine 1.1 177 Noncompetitive 1.0 458 111 Mixed 1.0
Diazepam 1.8 47 Noncompetitive 1.0 9 Noncompetitive 1.2
Lorazepam 0.2 239 53 Mixed 1.0 65 17 Mixed 1.0
Oxazepam 5 519 Competitive 1.0 41 93 Mixed 1.2
Olanzapine 0.04 196 Noncompetitive 1.0 266 Noncompetitive 1.0
The Kis and Ki i values are inhibition constants on the slope (competitive) and on the intercept (noncompetitive), respectively.
In the case of mix-type inhibition, the lower Ki was used in the calculation.
The plasma concentration of oxazepam was from Court et al.,19) and those of the other drugs were from Gilman et al.24)
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Table 2. Drugs used in this study and the involvement of UGTs in
their metabolism.
Drug UGT isoforms Km ( mM)
Excretion as
glucuronide
Etoposide UGT1A125) 503 15–30z26)
Irinotecan UGT1A127) unknown unknown





Tamoxifen UGT1A421) 32 unknown
Tacrolimus UGT2B730) 449 unknown
Cyclosporine UGT2B731) 202 unknown





Diclofenac UGT1A312) 12 5–10z33)
UGT2B7 25
Acetaminophen UGT1A134) 9400 63z35)
UGT1A6 2200
UGT1A9 20900
Naloxone UGT1A336) unknown unknown
UGT2B7 unknown
Carbamazepine UGT2B715) 214 15z37)
Valproic acid UGT1A638) 3200 10z39)
UGT1A9 5200
UGT2B7 2100
Imipramine UGT1A340) 472 0.1–0.8z41)
UGT1A4 310
Clomipramine UGT1A340) unknown 0.1–0.8z41)
UGT1A4 unknown
Amitriptyline UGT1A340) 267 26z42)
UGT1A4 170
Desipramine UGT1A340) unknown 0.1–0.8z41)
UGT1A4 unknown
Diazepam unknown unknown unknown
Lorazepam UGT2B718) unknown 86z43)
UGT2B1519) unknown
Oxazepam UGT2B718) 203 67z45)
UGT2B1544) 32
Olanzapine UGT1A446) 227 25z47)
Milnacipran unknown unknown 30z48)
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oxazepam showed the 1＋IWKi values of 1.2 for the
morphine 6-glucuronosyltransferase activity. Since
most compounds more potently inhibit morphine
6-glucuronosyltransferase activity than morphine 3-
glucuronosyltransferase activity, the ratio of 3-
glucuronideW6-glucuronide in plasma would be in-
creased, changing the analgesic e‹cacy and the risk of
side eŠects.
Discussion
Morphine is mainly metabolized to 3- and 6-
glucuronides by UGT enzymes. Morphine 3-glucuroni-
dation is catalyzed by multiple isoforms such as
UGT2B7, UGT1A8, and UGT1A3 with relatively low
Km values (0.4–3.2 mM) as well as UGT1A10, UGT1A6,
UGT1A1, and UGT1A9 with relatively high Km values
(13–37 mM).3) In contrast, morphine 6-glucuronidation
is speciˆcally catalyzed by UGT2B7 (Km＝1.0 mM).3)
Collectively. UGT2B7 is recognized as a major isoform
catalyzing the glucuronidation of morphine. In the
presents study, we investigated the inhibitory effects of
21 drugs on the morphine glucuronosyltransferase
activities. Although the Km values of the morphine
glucuronosyltransferase activities are high as mM order,
the inhibitory effects were investigated with the sub-
strate concentrations at mM order by considering the
plasma concentrations in clinical practice11) and the
detection limits of morphine glucuronides in the HPLC
system.
Among 21 drugs used in the present study,
diclofenac, clomipramine, and amitriptyline have been
reported to aŠect the pharmacokinetics of morphine
in vivo. Tighe et al.11) have reported that the plasma
concentration of morphine 6-glucuronide was decreased
by 40z with co-administration of diclofenac.
Diclofenac is known to be mainly metabolized by
P450s, but also metabolized by UGTs (Table 2). The
a‹nity of diclofenac to UGT2B7 (Km＝25 mM) is higher
than that of morphine.12) In the present study, we found
that diclofenac potently inhibited the morphine
glucuronosyltransferase activities in a noncompetitive
manner. The extent of in vivo inhibition can be
predicted quantitatively by the calculation of 1W(1＋IW
Ki) from an in vitro study. The 1＋IWKi values by
diclofenac were 1.4, indicating that the change of the
plasma concentration would be due to the inhibition of
morphine glucuronidation by diclofenac. Ventafridda
et al.13) reported that co-administration of clomipramine
and amitriptyline increased the area under the curve
(AUC) of morphine approximately 2 fold in humans.
Tricyclic antidepressants including clomipramine and
amitriptyline are known to be substrates of UGT1A3
and UGT1A4 (Table 2). However, we found that
clomipramine (Ki values were 6–20 mM) and amitripty-
line (Ki values were 30–248 mM) strongly inhibited the
morphine glucuronidations. These results are in
accordance with a previous study by Wahlstrom et al.14)
reporting that clomipramine (Ki values were 56–90 mM)
and amitriptyline (Ki values were 80–160 mM) inhibited
morphine glucuronidations in human liver microsomes.
The 1＋IWKi values by clomipramine were at most 1.2,
but those by amitriptyline were 1.0, indicating that
the prediction of in vivo inhibition from in vitro data
might be unsuccessful. For drugs that are cleared
predominantly through CYP-mediated metabolism,
there is growing evidence that successful prediction of
in vivo drug interactions through the inhibition of
metabolism can be made from in vitro data. In contrast,
drugs that are mainly metabolized by UGT appear to be
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less well-predicted using in vitro data. This may be due
to the nature of UGT, latency restricting the access of
substrates or UDPGA and the removal of formed
glucuronide. Thus, for drugs that are mainly metabo-
lized by UGT, the calculation of 1＋IWKi may not
necessarily give a plausible prediction. We found that
imipramine and desipramine also prominently inhibited
the morphine glucuronosyltransferase activities.
Although the 1＋IWKi was at most 1.1, it might be
necessary to pay attention to the co-administration of
these tricyclic antidepressants with morphine.
By calculation of the 1＋IWKi value, it was predicted
that carbamazepine might cause drug-drug interactions
with morphine. Carbamazepine is mainly metabolized
by P450s, but also glucuronidated by UGT2B7
(Table 2).15) The a‹nity of carbamazepine to UGT2B7
(Km＝214 mM) is higher than that of morphine.15)
Although the contribution of UGT to carbamazepine
metabolism might be low, our data suggest that the
co-administration of carbamazepine and morphine
should be avoided in clinical practice.
We found that benzodiazepine agonists have inhibito-
ry eŠects on the morphine glucuronosyltransferase
activities. The order of inhibitory potencies was
diazepamÀlorazepamÀoxazepam. The results were
consistent with a previous report that these drugs inhibit
zidovudine glucuronosyltransferase activity catalyzed
by UGT2B7 in human liver microsomes.16,17) Lorazepam
and oxazepam are mainly metabolized by UGT2B7 and
2B15,18,19) whereas diazepam is mainly metabolized to
oxazepam by CYPs.20) It is clearly demonstrated that
these drugs are potent inhibitors of UGT2B7. Co-
administration of these benzodiazepine agonists with
morphine should also be avoided.
Tamoxifen and tacrolimus strongly inhibited the
morphine glucuronosyltransferase activities. Although
tamoxifen has been reported to be a substrate of
UGT1A4,21) it is a potent inhibitor of UGT2B7 (Ki
values were 27–81 mM), like tricyclic antidepressants.
Tacrolimus, which is a substrate of UGT2B7, inhibited
morphine glucuronosyltransferase activities with a
mixed type of competitive and noncompetitive inhibi-
tion (Ki values were 46–347 mM). A drug-drug interac-
tion between morphine and tamoxifen or tacrolimus
might be possible.
Recently, it was reported that ketoconazole, which is
a well-known inhibitor of CYP3A4, potently inhibits
the morphine glucuronosyltransferase activity catalyzed
by recombinant UGT2B7 (Ki values were 110–120
mM).22) The possibility has been suggested that CYPs
may interact with UGTs to modulate the function of
UGTs.23) The drugs showing potent inhibitory eŠects on
morphine glucuronidation (Table 1) were substrates
of CYPs (clomipramine, amitriptyline, tamoxifen:
CYP2D6, diclofenac: CYP2C9, diazepam, lorazepam:
CYP3A4). It would be interesting to investigate whether
possible interaction between these CYP isoforms and
UGT2B7 might be related to the inhibitory eŠects.
In conclusion, we found that tamoxifen, tacrolimus,
diclofenac, carbamazepine, imipramine, clomipramine,
amitriptyline, diazepam, lorazepam and oxazepam have
prominent inhibitory eŠects on morphine glucuronida-
tion. If patients receive morphine and these drugs simul-
taneously, drug-drug interactions may result in changed
analgesic e‹cacy and risk of side eŠects. Such under-
standing is important so that clinicians can choose the
proper drugs andWor dosages, and anticipate potential
drug-drug interactions.
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